RB1 and breast carcinoma: Another study conducted by Mouron et al. [41] included 251 patients with HR+ breast cancer and studied the role of ER, CDK4/6, and/or FGFR1 blockade alone or in combinations in Rb phosphorylation, cell cycle, and survival.